Product news

Canadian health officials have approved Merck's Januvia (sitagliptin phosphate monohydrate), a once-daily, oral medication in a new class of anti-hyperglycemic agents known as DPP-4 (dipeptidyl peptidase-4) inhibitors. Januvia is approved in combination therapy with metformin, a commonly prescribed diabetes medication, to improve blood sugar (glucose) control in adult patients with type 2 diabetes when diet and exercise plus metformin do not provide adequate glycemic control.     
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.